Solute Carrier Family 7 Member 11 (SLC7A11) (also known as xCT) belongs to the cystine/glutamate transporter protein, mainly involved in amino acid transport across the plasma membrane. The SLC superfamily is the second largest family of membrane proteins after the GPCR, which is one of the most important families of membrane transport proteins in human cell membranes. Lots of evidence suggested that SLC7A11 drives ferroptosis resistance. Therefore, SLC7A11 as a potential target in tumors might offer an alternative solution to get out of the dilemma (Read more about SLC7A11).
Data from Pharmsnap suggested that there is one clinical drug (Anti-xCT antibody-drug conjugate (Agilvax)) targeting SLC7A11, which is in preclinical development for tumor treatment. At present, it is well established that SLC7A11 promotes drug-resistance or chemo-resistance in cancer therapy. Therefore, the inhibition of SLC7A11 __expression__ and activity is favorable for tumor treatment.
To fully support researchers and pharmaceutical companies in their research on the SLC7A11 targeted drug research in tumors, CUSABIO presents SLC7A11 active protein with a 12-transmembrane-domain (Code: CSB-CF892171HU(A4)) to assist you in your research on the mechanism of SLC7A11 or its potential clinical value.
